Treatment and Dosing for Hospital-Acquired Pneumonia (HAP)
For adults with HAP, empiric antibiotic selection must be stratified by mortality risk and MRSA risk factors, with specific dosing regimens tailored to achieve optimal pharmacodynamic targets against both gram-positive and gram-negative pathogens. 1
Risk Stratification Framework
The 2016 IDSA/ATS guidelines provide a clear algorithmic approach based on two key decision points:
Step 1: Assess Mortality Risk
High-risk mortality factors include:
- Need for ventilatory support due to pneumonia
- Septic shock 1
Step 2: Assess MRSA Risk Factors
MRSA coverage is indicated if ANY of the following:
- Prior IV antibiotic use within 90 days
- Hospitalization in a unit where >20% of S. aureus isolates are methicillin-resistant
- MRSA prevalence unknown
- High mortality risk (as defined above) 1
Specific Treatment Regimens and Dosing
Scenario 1: Low Mortality Risk + No MRSA Risk Factors
Choose ONE of the following:
- Piperacillin-tazobactam 4.5 g IV q6h
- Cefepime 2 g IV q8h
- Levofloxacin 750 mg IV daily
- Imipenem 500 mg IV q6h
- Meropenem 1 g IV q8h 1
Scenario 2: Low Mortality Risk + MRSA Risk Factors Present
Choose ONE antipseudomonal agent:
- Piperacillin-tazobactam 4.5 g IV q6h
- Cefepime or ceftazidime 2 g IV q8h
- Levofloxacin 750 mg IV daily
- Ciprofloxacin 400 mg IV q8h
- Imipenem 500 mg IV q6h
- Meropenem 1 g IV q8h
- Aztreonam 2 g IV q8h
PLUS add MRSA coverage:
- Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL; consider loading dose 25-30 mg/kg IV × 1 for severe illness)
- OR Linezolid 600 mg IV q12h 1
Scenario 3: High Mortality Risk OR Recent IV Antibiotics (within 90 days)
Choose TWO antipseudomonal agents from different classes (avoid combining two β-lactams):
β-lactam options (choose one):
- Piperacillin-tazobactam 4.5 g IV q6h
- Cefepime or ceftazidime 2 g IV q8h
- Imipenem 500 mg IV q6h
- Meropenem 1 g IV q8h
Second agent (choose one from different class):
- Levofloxacin 750 mg IV daily
- Ciprofloxacin 400 mg IV q8h
- Amikacin 15-20 mg/kg IV daily
- Gentamicin 5-7 mg/kg IV daily
- Tobramycin 5-7 mg/kg IV daily
- Aztreonam 2 g IV q8h
PLUS add MRSA coverage:
- Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL)
- OR Linezolid 600 mg IV q12h 1
Critical Dosing Considerations
Prolonged Infusions for β-lactams
For patients with late-onset HAP or high MIC pathogens, prolonged 3-hour infusions significantly improve pharmacodynamic target attainment. This is particularly important for:
- Cefepime 2 g q8h as 3-hour infusion (achieves 95.3% probability of optimal exposure)
- Ceftazidime 2 g q8h as 3-hour infusion (achieves 94.5% probability)
- Meropenem 2 g q8h as 3-hour infusion (achieves 90.1% probability) 2
The rationale: β-lactams require time-dependent killing (T>MIC). Prolonged infusions maintain drug concentrations above the MIC for 86.82% of the dosing interval versus only 42.84% with standard 30-minute infusions 3.
Vancomycin Dosing Specifics
- Always use weight-based dosing: 15 mg/kg per dose
- Target trough levels: 15-20 mg/mL
- Loading dose 25-30 mg/kg IV × 1 for severe illness or septic shock
- Adjust frequency (q8h vs q12h) based on renal function 1
Special Populations and Modifications
Structural Lung Disease
If patient has bronchiectasis or cystic fibrosis: Always use TWO antipseudomonal agents regardless of other risk factors, as these conditions dramatically increase gram-negative infection risk 1
Severe Penicillin Allergy
If aztreonam is substituted for β-lactam therapy, must add specific MSSA coverage since aztreonam lacks gram-positive activity 1
Renal Dysfunction
All dosing regimens require adjustment for creatinine clearance. The guideline emphasizes this applies to all agents listed 1
Common Pitfalls to Avoid
Do not use two β-lactams together - they have overlapping mechanisms and provide no additional benefit while increasing toxicity risk 1
Do not omit MRSA coverage in high-mortality patients - even without traditional MRSA risk factors, the mortality risk alone justifies empiric coverage 1
Do not use fluoroquinolones or ceftriaxone as monotherapy - these have low probabilities (<90%) of achieving adequate pharmacodynamic exposure against HAP pathogens 2
Do not forget to adjust for local antibiograms - the 20% MRSA threshold and 10% resistance thresholds are guidelines; individual institutions should customize based on their surveillance data 1
Evidence Quality Note
These recommendations come from the 2016 IDSA/ATS guidelines, which represent the most authoritative and comprehensive guidance for HAP management. While the evidence quality is rated as "very low to low" due to the nature of pneumonia research, these remain strong recommendations because early appropriate antibiotic therapy is the only modifiable factor proven to decrease infection-related mortality 1. The guidelines explicitly prioritize ensuring ≥95% of patients receive empiric therapy active against their likely pathogens, accepting some overtreatment to prevent treatment failures that increase mortality.